Brokerages Set Janux Therapeutics, Inc. (NASDAQ:JANX) PT at $45.85

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) have earned an average rating of “Moderate Buy” from the fifteen analysts that are currently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation, nine have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $45.8462.

Several equities analysts have commented on the stock. JonesTrading decreased their price objective on shares of Janux Therapeutics from $50.00 to $28.00 and set a “buy” rating on the stock in a report on Tuesday, April 28th. Cantor Fitzgerald decreased their price objective on shares of Janux Therapeutics from $150.00 to $100.00 and set an “overweight” rating on the stock in a report on Friday, February 27th. Wall Street Zen upgraded shares of Janux Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, April 5th. Weiss Ratings upgraded shares of Janux Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, April 22nd. Finally, Guggenheim cut their price objective on shares of Janux Therapeutics from $68.00 to $58.00 and set a “buy” rating for the company in a research report on Friday, May 8th.

Janux Therapeutics Stock Performance

Janux Therapeutics stock opened at $13.15 on Friday. Janux Therapeutics has a 52 week low of $12.12 and a 52 week high of $35.34. The stock has a market capitalization of $801.89 million, a P/E ratio of -7.15 and a beta of 2.53. The stock has a 50-day simple moving average of $14.51 and a 200 day simple moving average of $15.14.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.13. The business had revenue of $3.73 million for the quarter, compared to the consensus estimate of $4.36 million. Research analysts forecast that Janux Therapeutics will post -1.7 earnings per share for the current year.

Insider Activity

In other Janux Therapeutics news, insider Janeen Noel Doyle sold 4,059 shares of Janux Therapeutics stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $14.03, for a total value of $56,947.77. Following the completion of the sale, the insider owned 75,941 shares in the company, valued at $1,065,452.23. The trade was a 5.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, VP Maria Dobek sold 2,038 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $14.17, for a total transaction of $28,878.46. Following the transaction, the vice president directly owned 32,270 shares in the company, valued at $457,265.90. This represents a 5.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 7.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Janux Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC grew its holdings in shares of Janux Therapeutics by 71.7% during the 1st quarter. AQR Capital Management LLC now owns 9,717 shares of the company’s stock worth $262,000 after purchasing an additional 4,059 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Janux Therapeutics by 18.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,403 shares of the company’s stock worth $583,000 after purchasing an additional 3,393 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Janux Therapeutics by 12.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 186,394 shares of the company’s stock worth $5,033,000 after purchasing an additional 20,657 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Janux Therapeutics by 82.9% during the second quarter. JPMorgan Chase & Co. now owns 247,424 shares of the company’s stock worth $5,715,000 after buying an additional 112,116 shares in the last quarter. Finally, Legal & General Group Plc grew its stake in Janux Therapeutics by 12.0% during the second quarter. Legal & General Group Plc now owns 47,353 shares of the company’s stock worth $1,094,000 after buying an additional 5,055 shares in the last quarter. Institutional investors and hedge funds own 75.39% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.